Project Name: Leeds Teaching Hospitals Foundation Trust NETS Service development joint working Project with Novartis UK. Project period: 25 months
Joint working project summary: The aim of the LTHT / Novartis joint working project will be to deliver an improved NETs service able to provide better patient care and outcomes for NETs patients across West Yorkshire, through the following measures • Formalisation of the neuroendocrine tumour network across West Yorkshire. • Improvement in the quality of service provided for patients with neuroendocrine tumours by the development of different clinical management models such as nurse led follow-up and remote long term surveillance (both in and outside hospital ) with the aim of increasing patient service satisfaction. • To improve access to innovative medicines and treatment for NETs patients in the region. • Manage the development project so that it achieves its deliverables on time and secure long term funding for the NETs Clinical Nurse Specialist (CNS).
Expected patient outcomes for this project: Stratification of patients into new models of care e.g. Nurse led clinic and key worker support, will reduce patient waits and increase support provided and deliver more appropriate patient management. Measured by improvement in patient satisfaction with the service provided. An established NETs database and referral guidelines with improved network links will ensure all appropriate patients are referred and captured to provide equity of quality NETS care for all NETs patients across the region.
Start Date & Duration: March 2015 – April 2017
SAN14-C043c December 2015
James Paget University Hospital NHS Foundation Trust
Project Name: James Paget Hospital Nurse Led Service Development Project. Project period: 15 months
Joint working project summary:
James Paget Haematology team at University Hospital NHS Foundation Trust and Novartis will work in partnership on a joint working project with the aim to develop: (i) a new Clinical Nurse Specialist (CNS) led clinic for the treatment of Myelofibrosis (MF) / Myelodysplastic Syndrome (MDS) patients; and (ii) a new service for Chronic Myeloid Leukaemia (CML) patients whereby there will be regular assessment of molecular responses using the Novartis Treatment Evaluation Polymerase Chain Reaction (PCR) Tracker.
The NHS team will also develop a new MF/MDS treatment and care protocol, which will include blood transfusion and iron overload treatment, introduce regular health screening for all CML patients on TKI therapy and aim to improve patient satisfaction and financial sustainability of the service after the project has completed.
A project team will review and measure the impact of this service, with the results included in a Joint Working Project (JWP) summary report and a business case of the new service.
Expected patient outcomes for this project:
A new specialised and tailored CNS led clinic service, in the James Paget University Hospital NHS Foundation Trust to enhance the quality of care for MF/MDS patients.
Improve the average MF/CML/MDS patient satisfaction results.
All MF/MDS patients average symptom score assessed, 6 monthly, using the MPN10 symptom score assessment to identify patient in need of a treatment review with reference to the British Committee of Standards in Haematology (BCSH) guidelines vs baseline.
Using the Novartis Treatment Evaluation PCR Tracker, quarterly, improve CML patient outcomes by increasing the proportion of CML patients meeting the optimum molecular response standards of the European Leukaemia Network 2013 (ELN).